Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrin Tahri

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Cancer Research Communications|November 29, 2023
Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple MyelomaTarek H Mouhieddine, Chidimma Nzerem, Robert Redd, et al.
Nature Immunology|April 10, 2024
An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myelomaMadelon M E de Jong, Cathelijne Fokkema, Natalie Papazian, et al.
Blood Advances|August 6, 2024
Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myelomaSabrin Tahri, Sara Piccinelli, Nang Kham Su, et al.
Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.
Nature Communications|June 14, 2020
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantTarek H Mouhieddine, Adam S Sperling, Robert Redd, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Cancer Research Communications|November 29, 2023
Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple MyelomaTarek H Mouhieddine, Chidimma Nzerem, Robert Redd, et al.
Nature Immunology|April 10, 2024
An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myelomaMadelon M E de Jong, Cathelijne Fokkema, Natalie Papazian, et al.
Blood Advances|August 6, 2024
Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myelomaSabrin Tahri, Sara Piccinelli, Nang Kham Su, et al.
Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.
Nature Communications|June 14, 2020
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantTarek H Mouhieddine, Adam S Sperling, Robert Redd, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Pageof 2